Rhabdomyolysis after the use of tranexamic acid in a patient with hereditary angioedema

Authors

  • Emilie Karan Maia Centro Universitário de Brasília - UniCEUB
  • Fernanda Casares Marcelino Secretaria de Estado de Saúde do Distrito Federal - SES-DF
  • Fernanda Suelen Jacques Sousa de Assis Hospital Universitário de Brasília - HUB
  • Carmen Déa Ribeiro de Paula Hospital Universitário de Brasília - HUB

DOI:

https://doi.org/10.51723/ccs.v30i03.456

Keywords:

Hereditary angioedema, Tranexamic acid, Rhabdomyolysis

Abstract

The hereditary angioedema, a genetic disorder with exacerbated bradykinin production and generalized edema, has different symptoms that arise without any causal factor. Treatment consists of the use of rescue medications during crises and short- and long-term prophylaxis. Objective: to report the case of a patient treated with tranexamic acid, an antifibrinolytic agent, who had elevated urea, creatinine and creatine phosphokinase, receiving the diagnosis of acute kidney injury by rhabdomyolysis. After discontinuing the drug, kidney function improved and the enzyme decreased. Conclusion: rhabdomyolysis is an effect described with the use of epsilon-aminocaproic acid, but not with tranexamic acid.

Downloads

Download data is not yet available.

Author Biographies

Emilie Karan Maia, Centro Universitário de Brasília - UniCEUB

Estudante de Graduação do Curso de Medicina

Fernanda Casares Marcelino, Secretaria de Estado de Saúde do Distrito Federal - SES-DF

Médica Alergologista do Hospital Regional da Asa Norte - HRAN - SES-DF 

Fernanda Suelen Jacques Sousa de Assis, Hospital Universitário de Brasília - HUB

Médica Residente de Dermatologia do HUB

Carmen Déa Ribeiro de Paula, Hospital Universitário de Brasília - HUB

Médica Dermatologista do HUB

References

Ferraro MF, Ferriani MPL, França AT, Fusaro G, Garcia JFB, Komninakis S, et al. Diretrizes brasileiras para o diagnóstico e tratamento do angioedema hereditário – 2017. Arq Asma, Alerg e Imunol. 2017;1:23–48.

Bork K, Meng G, Staubach P, Hardt J. Hereditary Angioedema : New Findings Concerning Symptoms , Affected Organs , and Course. Am J Med. 2006;119:267–74.

Kanani A, Betschel SD, Warrington R. Urticaria and angioedema. Allergy, Asthma Clin Immunol [Internet]. 2018;14(s2):1–13. Available from: https://doi.org/10.1186/s13223-018-0288-z

Lumry WR. Current and Emerging Therapies to Prevent Hereditary Angioedema Attacks. Am J Manag Care. 2017;24(14):299–307.

Maurer M, Maferl M, Ansotegui I, Aygoren-Pursun E, Betschel S, Bork K, et al. The international WAO / EAACI guideline for the management of hereditary angioedema — The 2017 revision and update. Eur J Allergy Clin Immunol. 2018;73(December 2017):1575–96.

Martins S, Salgado M, Raposo F, Pinto D, Martinho I, Araújo R. Angioedema recorrente – caso clínico. Rev Pediatr do Cent Hosp do Porto. 2014;XXIII(1):21–4.

Valle SOR, França AT, Campos RA, Grumach AS. Angioedema hereditário. Rev bras alerg imunopatol. 2010;33(3):80–7.

Cabral GG, Monice LM, Machado LRD, Caldeira LML, Silva LR e, Couto H de A. Insuficiência renal aguda devido à rabdomiólise. Acta Biomed Bras. 2012;3(2):42–7.

Dunn CJ, Goa KL. A Review of its Use in Surgery and Other Indications. ADIS DRUG Eval. 1999;57(6):1005–32.

Neto MP, Gonçalves RV, Machado CJ, Resende V. Fatores associados à variação da creatina fosfoquinase (CPK) em pacientes vítimas de trauma, submetidos à “Onda Vermelha”, com evolução à rabdomiólise. Rev Col Bras Cir. 2018;45(2):1–9.

Published

2020-12-08

How to Cite

1.
Karan Maia E, Casares Marcelino F, Jacques Sousa de Assis FS, Ribeiro de Paula CD. Rhabdomyolysis after the use of tranexamic acid in a patient with hereditary angioedema. Com. Ciências Saúde [Internet]. 2020 Dec. 8 [cited 2024 Oct. 2];30(03):41-5. Available from: https://revistaccs.espdf.fepecs.edu.br/index.php/comunicacaoemcienciasdasaude/article/view/456

Issue

Section

Clínica Assistencial